Ocugen, Inc. (OCGN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ocugen, Inc. (OCGN) closed at USD 0.84 on 2026-10-14, a change of -44.7 % over the past year, with a market capitalization of USD 275.93M.

Ocugen, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ocugen, Inc. key figures

Previous close

USD 0.84 (2026-10-14)

1-year change

-44.7 %

Market cap

USD 275.93M

Enterprise value

USD 263.87M

P/E ratio (trailing)

-3.13

P/E ratio (forward)

-3.21

EPS (trailing)

-0.26

EPS (forward)

-0.25

PEG ratio

n/a

Price to book

-16.61

Revenue growth

8.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.75

Employees

116

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ocugen, Inc.

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ocugen, Inc. and compare it with other stocks.